Please note that the “Davos Declaration” on combating AMR is now hosted by the International Federation of Pharmaceutical Manufacturers’ Associations (IFPMA), with follow-up work led by that organisation. Please see their website at for more details and the latest iteration of the Declaration and the subsequent Roadmap document, or contact

Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance

On January 21, 2016, the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance was launched at an event at the World Economic Forum in Davos, Switzerland.

When published in January 2016, the Declaration had been drafted, agreed and signed by 85 companies and nine industry associations from across the global pharmaceutical, diagnostics and biotechnology industries. As of April 1st, 2016, a total of 98 companies and 11 industry associations in 21 countries have added their signatures to it. 

In the Declaration, signatory companies call on governments to work with them to develop new and alternative market structures that provide more dependable and sustainable market models for antibiotics, and to commit the funds needed to implement them. These mechanisms are needed to provide appropriate incentives (coupled with safeguards to support antibiotic conservation) for companies to invest in R&D to overcome the formidable technical and scientific challenges of antibiotic discovery and development. These include mechanisms to ensure that, where appropriate, the pricing of antibiotics more adequately reflects the benefits they bring; and novel payment models that reduce the link between the profitability of an antibiotic and the volume sold. An integral part of these models is a reduced need for promotional activity by companies.

The Declaration also sets out a commitment to further action on drug resistance by its signatories, across three broad areas:

  • Reducing the development of drug resistance. The companies commit to encouraging better and more appropriate use of new and existing antibiotics, including through work that supports the antibiotic stewardship principles set out by the World Health Organization (WHO) Global Action Plan on antimicrobial resistance (AMR), and via improved education of clinicians. This support extends to promoting more judicious use of antibiotics in livestock, as part of a ‘one health’ approach.
  • Increasing investment in R&D that meets global public health needs. Recognising the need to increase research into new antibiotics, diagnostics, vaccines and other alternative treatments, the companies commit to a continuation and extension of collaborative initiatives between industry, academia and public bodies to improve how R&D in the field is done and provide greater opportunities for the scientific barriers to antibiotic discovery to be overcome.
  • Improve access to high-quality antibiotics for all. In light of the gaps that remain in global access to our existing antibiotics and vaccines, and the importance of ensuring that new generations of products are available to all those who need them, the signatories commit to supporting initiatives aimed at ensuring affordable access to antibiotics in all parts of the world, at all levels of income.

The Declaration remains a living document, with signatories free to add or remove their endorsement at any time.

The Review on Antimicrobial Resistance is not a signatory to the Declaration but it has assisted its development and supports its aims. The Review is hosting the Declaration on its website on behalf of the signatory companies.

Read the press notice here.

Read the industry declaration here.

The Declaration was followed in September 2016 by a “Roadmap for Progress”, signed by 13 major global pharmaceutical companies, which built on the Declaration by setting out more detailed commitments by companies to address AMR through action on several fronts, including:

  • Acting on environmental pollution associated with antibiotic manufacturing.
  • Supporting improved stewardship of antibiotics.
  • Supporting affordable access to new and existing antibiotics for the patients who need them.
  • Increasing open collaboration in antibiotic discovery efforts.

The Roadmap is available on the IFPMA website at